Medivir AB (OSTO:MVIR)

Q2 2026 Medivir AB Earnings Call Transcript

Aug 20, 2026 / 12:00 PM GMT

Release Date Price: kr1.86 (+10.06%)

Transcript

Key Points

Positve

Phase 1b2a data for fostroxacimab plus lenvatinib published in Clinical Cancer Research, validating the liver-targeted mechanism and tumor-selective efficacy.
First patient dosed in the randomized FLEX-HCC study in Korea, with recruitment progressing well and expected to complete within 12 months.
Oversubscribed directed share issue raised approximately SEK 140 million, strengthening the balance sheet and funding all three Phase 2 studies.
MIV-711 is now being developed for two rare bone indications (Perthes disease and osteogenesis imperfecta), both with no approved treatments and significant market potential.
Received notice of allowance for a U.S. combination patent covering fostroxacimab plus lenvatinib, providing protection until at least 2041 in key markets.
Cash position of SEK 253.5 million is sufficient into 2030, excluding potential partnering proceeds.
Strong investigator and patient organization engagement for the OI study, with five sites approved and enrollment expected to be fast.
Positive data from the VetBioLix partnership (MIV-701) in canine periodontitis expected in Q4 2026, a potential value driver without material development costs.

Negative

Net turnover decreased by SEK 0.3 million year-over-year, reflecting lower revenue.
Other external expenses increased by SEK 13.4 million quarter-over-quarter due to early recruitment in FLEX-HCC, impacting operating costs.
Operating loss of SEK 21.2 million, though improved, remains significant.
No approved treatment exists for second-line HCC, and the recent IMbrave251 study showed no benefit from continuing immunotherapy, highlighting the challenging competitive landscape.
The company faces uncertainty regarding the patent application in China, with no timeline for a decision.
MIV-711 has only been tested in adults, and there are potential risks when treating children, requiring careful safety monitoring.
The company is still early in pricing and market access work for Perthes disease, with estimates based on benchmarks that may not materialize.
The FLEX-HCC study results are not expected until the second half of 2027, leaving a long period before potential value inflection.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MEDIVIR.ST - Medivir AB
Q2 2026 Medivir AB Earnings Call
Aug 20, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you, operator, and welcome, everyone, to Medivir's webcast covering the second quarter of 2026.

And looking back, this was the quarter where a lot of things came together for us. The Phase 1b2a data for phostroxin combination with lamatinib was published in Clinical Cancer Research, which is one of oncology's most cited journals. And we also took the important sort of exciting next step as the first patient was dosed in the randomized FLEX-HCC study in Korea.

We secured funding to take MIV711 into a second rare bone indication, Perth's disease, through an oversubscribed directed share issue of approximately 140 million sick.

Pia will take you through the clinical progress in both Fostrox and MIV711, and Patrick will

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by FactSet. Analyst estimates data is sourced from both Refinitiv and FactSet, with priority given to Refinitiv data. Data is updated daily.